Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
105
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis

Masashi Sakayori1 Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
,
Jiro Terada1 Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, JapanCorrespondence[email protected]
,
Mitsuhiro Abe1 Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
,
Yasutaka Hirasawa1 Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
,
Kenichi Suzuki1 Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
,
Keiichiro Yoshioka1 Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
,
Kenji Tsushima2 Department of Pulmonary Medicine, International University of Health and Welfare, School of Medicine, Chiba286-8686, Japan
&
Koichiro Tatsumi1 Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
 show all
Pages 2295-2303 | Published online: 11 Jul 2019

References

  • Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–1952. doi:10.1016/S0140-6736(17)30866-828365056
  • Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829. doi:10.1183/09031936.0000520919996196
  • Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760–1769. doi:10.1016/S0140-6736(11)60405-421571362
  • King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092. doi:10.1056/NEJMoa140258224836312
  • Richeldi L. du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082. doi:10.1056/NEJMoa140258424836310
  • Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253. doi:10.1183/13993003.00026-201526647432
  • Okuda R, Hagiwara E, Baba T, Kitamura H, Kato T, Ogura T. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med. 2013;107(9):1431–1437. doi:10.1016/j.rmed.2013.06.01123849626
  • Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224–226. doi:10.1016/j.rmed.2013.11.00524269005
  • Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis: a real-world observational study. Pulm Pharmacol Ther. 2017;46:48–53. doi:10.1016/j.pupt.2017.08.01128843616
  • Yoon HY, Kim DS, Song JW. Efficacy and safety of pirfenidone in advanced idiopathic pulmonary fibrosis. Respiration. 2019;97(3):242–251. doi:10.1159/00049293730332670
  • Ogura T, Azuma A, Inoue Y, et al. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig. 2015;53(5):232–241. doi:10.1016/j.resinv.2015.06.001
  • Lancaster L, Morrison L, Auais A, et al. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: experience from 92 sites in an open-label US expanded access program. Pulm Ther. 2017;3(2):317–325. doi:10.1007/s41030-017-0049-z
  • Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824. doi:10.1164/rccm.2009-040GL21471066
  • Iwata T, Yoshino I, Yoshida S, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan oncology group 6711 L (PEOPLE Study). Respir Res. 2016;17(1):90. doi:10.1186/s12931-016-0398-427450274
  • The Japanese Respiratory Society. Idiopathic Interstitial Pneumonias: Diagnosis and Treatment. 3rd ed. Tokyo: Nankodo;2016:54–55.
  • Rubino CM, Bhavnani SM, Ambrose PG, Forrest A, Loutit JS. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther. 2009;22(4):279–285. doi:10.1016/j.pupt.2009.03.00319328861
  • Uehara M, Enomoto N, Oyama Y, et al. Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology. 2018;23(3):318–324. doi:10.1111/resp.1314528851013
  • Talley NJ, Ford AC. Functional Dyspepsia. N Engl J Med. 2015;373(19):1853–1863. doi:10.1056/NEJMra150150526535514
  • Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–391. doi:10.1007/s12325-014-0112-124639005
  • Lancaster LH, de Andrade JA, Zibrak JD, et al. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. Eur Respir Rev. 2017;26(146). doi:10.1183/16000617.0057-2017
  • Pan L, Gelzleichter T, Chen Y, Burg C, Limb SL, Nguyen L. Effect of pirfenidone on gastric emptying in a rat model. Pulm Pharmacol Ther. 2018;51:41–47. doi:10.1016/j.pupt.2018.06.00129944949
  • Itoh T, Koyabu K, Morimoto A, et al. Ameliorative effects of mosapride or rikkunshi-to on the suppression of gastrointestinal motility by pirfenidone in rats. Jpn Pharmacol Ther. 2012;40:405–411.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.